Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
MaxCyte, the provider of cell-engineering platform technologies, has announced it has signed a clinical and commercial license with Sana Biotechnology (SB).
SB creates and delivers engineered cells as medicines and treatments.
The license states that SB will have non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT platform.
MaxCyte will receive platform licensing fees and milestone payments.
Doug Doerfler, president and ceo of MaxCyte, said: This agreement represents an important achievement for MaxCyte as we continue to expand the use of our next-generation technology platform to support the development of innovative treatments.